Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 11626 - 11650 of 11745 in total
Vapitadine is an antihistamine that Barrier Therapeutics is developing as a treatment for allergic reactions of the skin, such as those associated with hives and for the itch associated with atopic dermatitis. An advantage of vapitadine over other antihistamines may be the absence of the sedation, even at high doses.
Investigational
Matched Description: … Vapitadine is an antihistamine that Barrier Therapeutics is developing as a treatment for allergic reactions …
MDI-P has demonstrated potent anti-HIV activity. MDI-P has been shown to be effective in killing HIV in cell culture. HIV is the virus that causes acquired immune deficiency syndrome (AIDS). MDI-P is also a potential therapeutic agent for the treatment of the symptoms of cystic fibrosis ("CF").
Investigational
Matched Description: … MDI-P is also a potential therapeutic agent for the treatment of the symptoms of cystic fibrosis ("CF …
Quaternium-18 is a mixture of quaternary ammonium chloride salts. Quaternium-18 Hectorite and Bentonite are the reaction products of Quaternium-18 with clays. These compounds are poorly absorbed through the skin. Acute oral and percutaneous toxicity tests in animals indicate that they exhibit little or no systemic toxic effects.
Experimental
Matched Description: … Quaternium-18 is a mixture of quaternary ammonium chloride salts. …
Lomerizine is a diphenylmethylpiperazine calcium channel blocker[A245378, A245383] with relatively selective central nervous system (CNS) effects. This drug is used to prophylactically treat migraines[A245368, A245373] and is also being investigated against eye-related diseases that are associated with local circulatory disturbances, an example being normal-tension glaucoma.
Experimental
Matched Description: … Lomerizine is a diphenylmethylpiperazine calcium channel blocker[A245378, A245383] with relatively selective …
Phosphorus P-32 is a radioactive isotope of phosphorus with beta particle-emitting radiocytotoxic activity. Emitted by phosphorus P32, beta particles directly damage cellular DNA and, by ionizing intracellular water to produce several types of cytotoxic free radicals and superoxides, indirectly damage intracellular biological macromolecules, resulting in tumor cell death.
Experimental
Matched Description: … Phosphorus P-32 is a radioactive isotope of phosphorus with beta particle-emitting radiocytotoxic activity …
CIGB-258 is a peptide that is immunoregulatory and derived from heat shock protein 60 of the cellular variant. As of 2020, The Center for Genetic Engineering and Biotechnology (CIGB) in Havana, Cuba, is testing the treatment efficacy of this peptide in patients with COVID-19 who are under intensive therapy regimens...
Investigational
Matched Description: … CIGB-258 is a peptide that is immunoregulatory and derived from heat shock protein 60 of the cellular …
Betameprodine is an opioid analgesic classified by the United States Drug Enforcement Administration under Schedule I of illegal substances. The stereoisomer alphameprodine is similarly classified, and was more widely used (both are referred to as Meprodine). Betameprodine is a structural analogue of meperidine. It exerts physiological effects characteristic of opioids,...
Experimental
Illicit
Matched Description: … Betameprodine is a structural analogue of meperidine. …
Urelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma. Urelumab is a fully human antibody that targets CD137. The antibody product was developed using Medarex's UltiMAb(R) technology and was the first UltiMAb- derived antibody in...
Investigational
Matched Description: … Urelumab is a fully human antibody that targets CD137. …
Investigational
DG031, deCODE genetics's lead compound, is being developed for the prevention of myocardial infarction, or heart attack.
Investigational
R-851 is part of the family of immune response modifier (IRM) and it acts in a novel way to stimulate the human body's immnune system to attack virus-infected cells and tumor cells. It is expected to be topical treatment for cervical displasia and cervical high-risk human papillomavirus (HPV), the sexually...
Investigational
Matched Description: … R-851 is part of the family of immune response modifier (IRM) and it acts in a novel way to stimulate …
Ketobemidone is a powerful opioid analgesic. It also has some NMDA-antagonist properties. This makes it useful for some types of pain that don't respond well to other opioids. The most commonly cited equalisation ratio for analgesic doses is 25 mg of ketobemidone hydrobromide to 60 mg of morphine hydrochloride or...
Investigational
Matched Description: … Ketobemidone is a powerful opioid analgesic. It also has some NMDA-antagonist properties. …
SYNB1353 is a strain of the probiotic bacteria Escherichia coli (E. coli) type Nissle and an engineered probiotic drug. Developed by Synlogic Operating Company, Inc., SYNB1353 is being investigated for the treatment of homocystinuria. It is designed to consume methionine in the gastrointestinal tract to prevent its absorption and conversion...
Investigational
Matched Description: … SYNB1353 is a strain of the probiotic bacteria _Escherichia coli_ (_E. coli_) type Nissle and an engineered …
Investigational
ETC-588, or LUV (large unilamellar vesicles), is made of naturally occurring lipids that circulate through arteries to facilitate the role of high-density lipoprotein (HDL) in removing accumulated cholesterol and other lipids from cells including those in the arterial wall. LUV are capable of transporting excess cholesterol from the vasculature to...
Investigational
Matched Description: … Esperion is currently developing ETC-588 as a treatment for patients with acute coronary syndromes. …
Used in the treatment of cancer, Marmiastat is an angiogenesis and metastasis inhibitor. As an angiogenesis inhibitor it limits the growth and production of blood vessels. As an antimetatstatic agent it prevents malignant cells from breaching the basement membranes.
Investigational
CAD106 is an immunotherapeutic product in development for the treatment of Alzheimer's disease. It is designed to induce antibodies against the beta-amyloid-protein that inhibit the formation of plaques in the brain of Alzheimer's disease patients.
Investigational
NS3728 is an orally active chloride channel blocker for the treatment of cancer.
Investigational
PN0621 is an anti-TNF, domain antibody (dAb) based therapeutic. It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis. It is being developed by Peptech.
Investigational
NV-18 is a product of the Novogen diphenolic synthetic analogue program that is creating drugs with diverse activities against specific types of cancer. Like phenoxodiol, NV-18 is broadly effective in the laboratory against almost all human cancer types, but NV-18 is distinctive in showing particular potency against melanoma and cholangiocarcinoma...
Investigational
Matched Description: … NV-18 is a product of the Novogen diphenolic synthetic analogue program that is creating drugs with diverse …
MEM 1414 is a PDE4 inhibitor that is being evaluated for the treatment of Alzheimer’s disease. This drug candidate has completed Phase 1 clinical trials. MEM 1414 works by blocking phosphodiesterase, an enzyme that breaks down an important brain chemical, cyclic AMP. It appears to work in the area of...
Investigational
Matched Description: … MEM 1414 is a PDE4 inhibitor that is being evaluated for the treatment of Alzheimer’s disease. …
Tolperisone is an oral, centrally acting muscle relaxant. Its precise mechanism is not completely understood, though it blocks sodium and calcium channels. It possesses a high affinity for nervous system tissue, reaching highest concentrations in brain stem, spinal cord and peripheral nerves. Based on existing clinical data, Tolperisone is not...
Investigational
Matched Description: … It possesses a high affinity for nervous system tissue, reaching highest concentrations in brain stem …
Firocoxib is a cycooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug. It currently approved for veterinary use in dogs and horses under the brand names Equioxx and Previcox. Firocoxib was the first COX-2 inhibitor approved by the U.S. Food and Drug Administration for horses. Firocoxib is not intended or approved for use...
Experimental
Vet approved
Matched Description: … Firocoxib is a cycooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug. …
Displaying drugs 11626 - 11650 of 11745 in total